United Kingdom (UK)
Recombinant monoclonal antibody to Envelope protein domain III. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma POWV-80.
UniProt Accession Number of Target Protein: Q91LY1
Alternative Name(s) of Target: Core protein; Envelope protein E; Matrix protein; Peptide pr; Protein pr; Small envelope protein M; POWV
Immunogen: The original antibody was originated by immunizing C57BL/6J mice with POWV-SPO.
Specificity: The antibody binds to domain III of the envelope protein. The antibody cross reacts with tick-borne encephalitis virus (TBEV) and LGTV.
Application Notes: The specificity of the antibody (IgG2c) was determined by ELISA. The antibody was used for flow cytometric analysis of HEK-293T cells. The antibody showed neutralizing activity on Vero cell incubated with POWV MA51240. The antibody showed neutralizing activity also against TBEV and LGTV (EC50 respectively 8.4 and 103 ng/ml). The binding affinity of the antibody to POWV E was measured using biolayer interferometry (BLI), showing the antibody binds POWV E with an affinity (KD) of ∼30 nM. The crystal structure of the Fab fragment in complex with POWV DIII was determined. The antibody might have therapeutic potential (VanBlargan et al., 2021; PMID: 33831142).
Antibody first published in:
VanBlargan Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses. J Exp Med. 2021 May 3;218(5):e20210174 PMID:33831142
Note on publication:
The paper describes the development of a panel of neutralizing anti-Powassan virus antibodies.